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Introduction
 Varicella-zoster virus (VZV) infection is a highly 
contagious but usually benign and self-limiting disease 
in otherwise healthy children. On the other hand, 
immunocompromised children are at great risk of suffering 
from severe, prolonged, and complicated varicella. It 
can result in disseminated disease, pneumonia, hepatitis, 
encephalitis and death (Albrecht, 2009). Before the 
introduction of effective antiviral therapy, the mortality 
rate of varicella in cancer children receiving chemotherapy 
was around 7% in a Western country (Feldman et al., 
1975). Severe complications were more likely to develop 
in patients with acute leukemia than in those with other 
malignancies (Feldman and Lot, 1987). 
 Nosocomial transmission of varicella is an ever more 
serious problem. The increasing number of childhood 
cancer patients receiving chemotherapy suggests that a 
greater number of children will be at risk for varicella. 
Although reports of varicella outbreaks in hospital are rare, 
some of them were in a pediatric oncology unit (Kavaliotis 
et al., 1998; Adler et al., 2008). 
 Several recommendations have been made by the 
American Academy of Pediatrics (AAP) to prevent the 
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Abstract
 Background: Varicella is highly contagious and dangerous disease especially in immunocompromised 
patients. Children with cancer are at increased risk of severe illness and fatal cases occur. Objective: To describe 
an outbreak of varicella among in-patient cancer children, family members and staff. Estella Children Cancer 
Center in Manado, Indonesia with 14 beds and a 15 bed capacity guest house for family members. Methods: A 
retrospective study of patients, family members and staff who were diagnosed with varicella based on clinical 
appearance was performed. Follow up was until 28 days from the last patient diagnosis’ date.  Results: From late 
February to early May 2009, varicella was affecting 4 among 8 children with leukemia, 1 family member and 
1 housekeeping staff. Measurers taken after the index case were oral acyclovir both for patients and contacts, 
patient isolation, ward disinfection and some chemotherapy interruption. Nevertheless, a second and third wave 
of varicella occurred.  The index case died due to encephalitis. Other patients were non-severe and cured, but 
one child was lost to follow up. Conclusions: This outbreak highlights the importance of proper prevention and 
prompt management of varicella in immunocompromised patients. Simple and locally applicable guidelines are 
needed.
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transmission of varicella in healthcare settings, including 
treatment and isolation of hospitalized infected patients 
and management of susceptible contacts (AAP, 2009). 
However, implementation of such recommendations in 
limited resources setting needs adjustments (Jain et al., 
2000). 
 We describe an outbreak of varicella among 
hospitalized acute leukemia children, family members 
and hospital staff. The management of this outbreak was 
evaluated in regard to limited resources. 
Materials and Methods
Clinical setting 
 Estella Children Cancer Center is a freestanding clinic 
on the grounds of RD Kandou academic hospital. It is 
located in Manado, Indonesia and has a capacity of 14 
beds. It consists of two third-class wards with four beds 
each, a second-class ward with 3 beds, a first-class ward 
with 2 beds and isolation room with 1 bed. Most patients 
are poor and can not afford treatment by themselves but 
they get support from the Indonesian Government Welfare 
Program (GAKIN) and/or the Dutch Estella Fund. Estella 
center is equipped with a separated guesthouse where 
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family members can reside during treatment. It comprises 
4 sleeping rooms with a total of 15 beds, sharing kitchen 
and toilet. 
Design 
 A retrospective study of patients, family members 
and hospital staff who were diagnosed as varicella was 
performed. The study period was from the fourth week 
of February 2009 when the index case was diagnosed, 
to the first week of May 2009, i.e. 28 days from the last 
patient diagnosis’ date. Diagnosis of varicella was based 
on clinical appearance, namely an acute generalized 
maculopapulovesicular rash, without other apparent cause. 
Patient’s parent gave informed consent. Ethics Committee 
of RD Kandou General Hospital Manado approved this 
study.
Results
 Over a period of around 10 weeks between the last 
week of February 2009 to the first week of May 2009, 4 
cases of varicella were diagnosed among 8 children with 
acute leukemia (7 acute lymphoblastic leukemia [ALL] 
and 1 acute myeloblastic leukemia [AML]), 1 case of 
family member and 1 case of housekeeping staff. All 
varicella patients with acute leukemia were those with 
ALL. Table 1 showed the characteristics of ALL children 
who suffered from varicella. The children with ALL were 
treated according to the Indonesia-2006 protocol, which is 
based upon dexamethasone in induction and reinduction 
(for high risk patients only), and in pulses of 2 weeks every 
8 weeks during maintenance.
 The index case was a hospitalized 10 year-old girl with 
T-lineage ALL in induction phase (case patient 1, Figure 
1). She had a rash for approximately 2 days before the 
appearance of more papules on her limbs and face were 
brought to the attention of doctors and a diagnosis of 
varicella was made. She was moved to an isolation room 
of the tropical/infectious disease ward in a distance of 10 
meters from Estella-cancer ward. She was treated with 
oral acyclovir. Her intrathecal methotrexate (IT MTX), 
intravenous doxorubicine and L-asparaginase were 
withheld, but her steroid was continued. She developed 
seizures and unconsciousness 2 days after having skin 
lesions. She was diagnosed with encephalitis and died 1 
day later. No known source of infection was recognized. 
 Eighteen days after the index case, 1 child and 1 
housekeeping staff had varicella diagnosed. The second 
case was a 4½-year-old girl with precursor-B ALL in 
induction phase of treatment (case patient 2). She was 
given oral acyclovir, continued the steroid and discharged 
from hospital on the next day by her parent request. She 
never came back to continue her treatment and is lost 
to follow up.  The housekeeper was treated with oral 
acyclovir in her home until recovery.
  A mother of case patient 3 was diagnosed 7 days 
after the second wave. Her daughter (case patient 3), 3½ 
years, presented with papulovesicular lesions on her face, 
head and back 14 days after the second wave. She was in 
maintenance phase during dexamethasone block. The last 
case patient was a 6 year-old girl with precursor-B ALL in 
maintenance phase on 6-mercaptopurine and methotrexate 
without dexamethasone block. She presented with lesions 
Table 1. Characteristics of Varicella in Children with Acute Leukemia
Case Leukemia Phase of Varicella WBC/µL Lymphocyte AST ALT Chemotherapy Outcome
Patient  treatment manifestation  count/µl  (U/L) (U/L) withheld/continued 
1 T-lineage  Induction Lesions on 3200 1088 189 63 Withheld IT MTX,  Died
 ALL, HR week 4 face, trunk,      Continued
   limbs.     Dexamethasone
   Encephalitis  
2 Precursor- Induction Lesions on 2300 1357 95 289 Withheld Lost to
 B ALL,  week 3 head, back     doxorubicine iv,  follow up
 SR       Continued 
        Dexamethasone 
3 Precursor- Maintenance,  Lesions on 900 702 145 65 Withheld Cured
 B ALL,  week27 face, head,      dexamethasone
 SR  back     block
4 Precursor- Maintenance,   Lesions on 3300 1188 34 31 Continued 6-MP Cured
 B ALL,  week 19 head, neck     & Methotrexate
 HR    
WBC: white blood cell, AST: aspartate amino transferase, ALT: alanine amino transferase
Figure 1. Flow Diagram of Patients Involved in the 
Outbreak of Varicella
Index case (case patient 1) 
Diagnosed 24/02/2009 
Died 27/02/2009  
Case patient 2 
Diagnosed 14/03/2009 
Lost to follow up 
Case patient 3 
Diagnosed 30/03/2009 
Cured 13/04/2009 
Case patient 4 
Diagnosed 04/04/09 
Cured 21/04/2009 
Housekeeping staff 
Diagnosed 16/03/2009 
Cured 24/03/2009 
18 d 20 d 
14 d 19 d 
Mother of case patient 3 
Diagnosed 23/03/09 
Cured 28/03/2009 
7 d 
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on head and neck (case patient 4). Both patients received 
oral acyclovir and were placed in isolation. The mother of 
case patient 3 was treated with oral acyclovir and stayed 
in her home. The flow diagram of patients involved in the 
outbreak of varicella is presented in Figure 1.
 Four other inpatient children who were exposed to 
the varicella cases were managed with oral acyclovir as 
well. Two children with ALL and one child with AML 
were discharged. Another child with relapsed ALL in 
induction phase was moved to other non-infectious general 
pediatric ward to continue her treatment. At day 20 from 
the diagnosis date of index case, the whole cancer ward 
was cleaned and disinfected.
 There was no history of previous varicella infection 
and/or vaccination in the case patients, family members 
and housekeeping staff, as well as the non-infected acute 
leukemia patients. At the time of outbreak, 4 family 
members stayed in the guest house and were in contact 
with varicella. These otherwise healthy contacts were 
advised to avoid exposure as much as possible and to 
do the general precaution properly (hand-washing, face 
mask, etc). There was no policy to ask specifically about 
varicella or vaccination history.
Discussion
 This was the first varicella outbreak that occurred in 
our center from its opening in 2006. Strict isolation was 
not properly implemented in our case. Although the index 
case was isolated in a separate building and the following 
cases were put in isolation room in Estella ward, the family 
members still met each other in the guesthouse and the 
patients themselves might go around in the corridor. At 
the moment of isolation, the index case had had a rash for 
several days, so she was infectious probably already about 
a week. The second wave could probably not have been 
prevented. However, notwithstanding the taken measures, 
including closing the ward for disinfection, isolating the 
cases, still a third wave of varicella occurred. Indeed, 
nosocomial outbreaks of varicella continue to occur even 
in modern hospitals. The nosocomial spread of varicella 
is by direct exposure; by contact fomites, as well as by 
airborne transmission of the virus [Kavaliotis, et al., 1998]. 
Modern hospitals are frequently constructed with central, 
re-circulating ventilation systems. This might promote 
airborne spread of microorganisms. Gustafson et al. (1982) 
reported an outbreak of airborne nosocomial varicella. 
Although strict isolation was applied to the index case, an 
outbreak of varicella did occur in the ward. In their case, 
the pressure in isolation room was more positive to that of 
in the corridor. It was suggested that patients hospitalized 
with varicella be placed in negative-pressure isolation 
room. A similar finding was reported by Sawyer et al. 
(1994). VZV DNA was detected in 82% of air samples 
from rooms housing patients with active varicella, in a 
distance of 1.2-5.5 meters from patients’ bed and for 1-6 
days following onset of rash.
 Recently, Adler et al. (2008) reported a comparable 
outbreak. A varicella outbreak occurred in a pediatric 
oncology unit with outpatient clinics, and affiliated group 
housing and schoolroom spaces. The housing facility and 
schoolrooms were places where immunocompromised 
children, parents, and healthy siblings from multiple 
families shared common fomites, providing abundant 
chance for varicella transmission. Additionally, the 
residents of the housing facility often visited daily the 
inpatient and outpatient hospital clinic, which resulted in 
exposure to the case patient. In response to the outbreak, 
policy at the residential facility was changed. All staff 
and visitors were asked regarding history of varicella or 
its vaccination. Information and education materials on 
varicella were provided. Active surveillance for signs and 
symptoms of varicella, relocation of families without a 
history of varicella or its vaccination, and prophylaxis 
for the immunocompromised patients living at the house 
were performed.
 Prolonged skin lesions were present in two of our 
cases, except for the index case who died early. The 
elevation of liver transaminases was not accompanied 
with other sign or symptom of hepatitis. None of our 
patients had a lymphocyte count less than 500/µl. 
Feldman and Lott (1987) reported that more severe VZV 
infections happened in immunocompromised patients, 
especially in those with impaired cell-mediated immunity. 
Lymphopenia (absolute lymphocyte count <500/ µl) 
was significantly associated with VZV pneumonia and 
higher fatality rate. These patients are more likely to 
suffer from disseminated disease with extensive skin 
lesions, pneumonia, encephalitis, hepatitis, or other 
visceral involvement. The most common varicella-related 
mortality was secondary bacterial infections especially 
pneumonia (Nguyen et al., 2005). 
 All varicella cases in this study received oral acyclovir 
instead of the standard intravenous (iv) acyclovir. Oral 
acyclovir is much cheaper than the iv one and available 
in the government essential drug list. All came from 
either poor families or civil servant familes that had 
healthcare subsidy or insurance from the government. 
Few reports supported the effectiveness of oral acyclovir 
in immunocompromised but uncomplicated varicella 
children (Meszner et al., 1993; Jain et al., 2000).
 Due to the skin lesions, IT-MTX was withheld in our 
index case. Steroid was continued in index case and in 
case patient 2 since they were in induction phase. On 
the other hand, steroid was cancelled in case patient 3 
in maintenance phase. There is evidence that prednisone 
therapy during the incubation period of VZV (10-21 days) 
increases significantly the risk for developing severe 
varicella infection. It is possible that dexamethasone is 
even more dangerous in this respect. Patients who are on 
ALL treatment and are exposed to varicella should have 
steroid therapy deferred until after the incubation period. 
The exception of this approach may be children who are 
exposed during the ALL remission induction phase. It is 
probably safe to continue antimetabolite therapy such 
as 6-mercaptopurine and methotrexate, and vincristine 
during a VZV incubation period (Hill et al., 2005).
 In our setting, all patients who were exposed to 
varicella but non-affected were given prophylactic oral 
acyclovir. No prophylaxis was provided to healthy 
contacts. Both intravenous immunoglobulin (IVIG) 
and varicella vaccine are expensive and varicella-zoster 
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immunoglobulin (VZIG) is not available in Manado. 
 There are 2 principal means of post-exposure 
prophylaxis in immunosuppressed children i.e. 
intramuscular VZIG and oral acyclovir or valacyclovir 
(Weinstock et al., 2004; Skinner et al., 2008. The majority 
of published literature regarding post-exposure prophylaxis 
of VZV relates to VZIG. The use of antiviral agents is 
not supported by randomized trials, but uncontrolled 
experience suggests that it might be a reasonable option 
if VZIG is not available (Boeckh, 2006(. In UK, post-
exposure prophylaxis is not currently recommended for 
patients with prior evidence of seropositive VZV antibody, 
except after hematopoietic stem cell transplantation. 
Prophylaxis is given only to patients without serum 
varicella-zoster immunoglobulin G antibody (VZIgG) 
at diagnosis of their malignancy. However, this was 
questioned due to the occurrence of varicella in a number 
of immunocompromised children who all showed VZIgG 
positivity at diagnosis of their malignancy (Manley et 
al., 2008). Post-exposure varicella vaccination may be 
offered to child and adult household contacts without 
evidence of immunity of immunocompromised persons. 
It is recommended to vaccinate within 3-5 days from 
exposure to varicella (CDC, 2007).
 Varicella vaccination has not yet been recommended 
as universal immunization in Indonesia and is not 
provided routinely for cancer survivor children. Buda 
et al. (1996) found that varicella exposure and infection 
were common in children receiving maintenance therapy 
for ALL. Analysis of 472 children during maintenance 
period showed 120 exposures to varicella (10/100 patient-
years) and 60 cases of varicella (4.6/100 patient-years). 
Varicella vaccination has been recommended for selected 
children with ALL in remission. During maintenance 
phase, the vaccine can be administered after at least 1 
year in remission, lymphocyte count >700/µl, and platelet 
count >100,000/µl. Chemotherapy should be suspended 
1 week before until 1 week after vaccination (Sartori, 
2004; AAP, 2009). Experience in VUmc Amsterdam 
with varicella vaccination given in induction for ALL 
was negative. Several patients developed severe vaccine-
related varicella, so we stopped. Fortunately, in VUmc 
we saw no lethal consequences. Schrauder et al. (2007) 
reported a fatal experience.  They suggested postponing 
varicella vaccination until at least 9 months after the end 
of chemotherapy (including maintenance therapy) and 
not before lymphocyte count of at least 1500/µl. This of 
course does not help patients during chemotherapy when 
they are most endangered.
 In conclusion, this outbreak highlights the importance 
of proper prevention and prompt management of varicella 
in immunocompromised patients.  We believe that in 
limited resources settings, oral acyclovir administration 
seems quite satisfactory in managing varicella exposures 
in immunocompromised children. Simple and locally 
applicable guidelines are needed.
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